Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout.  

The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund.  

The financing round will support the advancement of global Phase III clinical studies evaluating the company’s lead asset, dotinurad. The treatment is a next-generation, once daily oral, URAT1 inhibitor with potential best-in-class safety and efficacy for the treatment of gout.  

Dotinurad has already demonstrated robust efficacy and a well-defined safety profile across multiple clinical studies, supporting its approval in Japan, China, Philippines and Thailand. 

“Crystalys was built to bring forward a new therapeutic option for the millions of people struggling with gout,” said James Mackay, President and Chief Executive Officer of Crystalys Therapeutics. “Our lead asset, with its proven efficacy and well-defined safety profile, has already demonstrated its ability to provide meaningful relief for people living with gout. Thanks to the support of our investors, our experienced team is now well-positioned to accelerate dotinurad’s development in the US and Europe as a much needed second-line therapy for patients who do not respond adequately to first-line treatments.” 

Gout is the most common form of inflammatory arthritis, characterised by sudden, severe attacks of pain, swelling, redness and tenderness in one or more joints. The disease arises from excess uric acid in the body, known as ‘hyperuricemia,’ which causes buildup of uric acid crystals and inflammation, leading to tophaceous gout in people with chronic or undertreated disease.  

Although therapies are available to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors (XOIs) and last-line uricase therapy. Currently, no suitable second-line options exist in the US or EU, leaving a critical unmet need for patients who fail to respond to first-line treatments. 

“The clinical effectiveness of dotinurad for treating hyperuricemia associated with gout has already been well validated across 22 trials involving 1,300 subjects. Since its approval in Japan in 2020, more than 1.2 million patients have been treated with dotinurad, consistently achieving target serum uric acid levels linked to meaningful clinical benefits,” said Nihar Bhakta, Chief Medical Officer of Crystalys Therapeutics. “Our upcoming Phase III trials are designed to highlight the superior efficacy of dotinurad in reducing serum uric acid levels, gout flares and tophus area.”

Bruno Quinney, Content Team, DDW